Introduction
============

*Streptococcus agalactiae* or group B streptococcus (GBS) is a pathobiont that is often part of the normal microbiota found in the gastrointestinal and genitourinary tracts of healthy women ([@B156]). It can cause serious neonatal infections and adult infections. During the early 1930s, GBS was initially identified as a veterinary pathogen and a frequent source of bovine mastitis ([@B63]). The first reported cases of fatal human GBS infections were investigated by [@B42]. Severe perinatal GBS infections were originally described in the 1960s ([@B53]). Shortly afterward since the 1970s, GBS emerged as a leading cause of neonatal mortality and morbidity in the United States ([@B26]).

The gastrointestinal tract is recognized as a reservoir for GBS and represents most probably the source of vaginal colonization ([@B104]). Maternal colonization is the principal route of GBS transmission in early-onset infections as bacteria can spread either *in utero* by ascending infection or during birth through neonatal aspiration of contaminated amniotic or vaginal fluids ([@B94]; [@B117]; [@B156]). About 30--70% of colonized mothers deliver GBS colonized newborns and 1--2% of these develop early-onset infections where heavy colonized mothers are more likely to transmit GBS to their offspring ([@B6]; [@B9]; [@B102]; [@B103]). However, the route for GBS acquisition in late-onset infections is less clear. It may develop through vertical transmission from mother to neonate, nosocomial transmission, contaminated breast milk or prematurity ([@B117]; [@B78]; [@B161]).

Group B streptococcus diseases in neonates which develop within the 1st week after birth are designated as early-onset disease (EOD). Late-onset infections (LOD) develop between the 7th day of birth and 2 or 3 months of age. Early-onset infections usually manifest as pneumonia and sepsis while meningitis is most common as a Late-onset event ([@B156]; [@B103]). Newborns with EOD frequently suffer from respiratory failure which rapidly develops into bacteremia and septic shock. Infants surviving LOD meningitis will develop chronic neurologic sequelae including seizures, cognitive impairment, hearing loss and blindness in up to 50% ([@B131]; [@B94]; [@B82]; [@B103]).

During the mid-1990s, the American College of Obstetricians and Gynecologists (ACOG), Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP) recommended intrapartum antibiotic prophylaxis (IAP) to prevent perinatal GBS disease ([@B131]). This was followed by revised guidelines for the prevention of GBS disease issued in 2002 and the updated guidelines in 2010 ([@B156]; [@B129]) which are currently in use. These recommendations included a universal culture-based screening for pregnant women at 35--37 weeks of pregnancy in order to limit IAP to a certain risk group. Widespread active implementation of an IAP program in the United States resulted in an outstanding decrease in the incidence of the disease. Invasive EOD GBS infections declined from 1.8 cases/1000 live births in the early 1990s to 0.26 cases/1000 live births in 2010 ([@B129]). However, IAP had no impact on late-onset infections and thus LOD GBS diseases continue as the leading cause of neonatal morbidity and mortality ([@B156]; [@B129]).

Asymptomatic GBS carriage is frequent and in general harmless in healthy women. GBS can, however, cause serious infections in pregnant women. Invasive maternal illness due to GBS in pregnant and postpartum women include bloodstream infections, meningitis, osteomyelitis, and endocarditis. Non-invasive maternal diseases manifest as bacteriuria, amnionitis, fasciitis, cellulitis, endometritis and wound infections associated with episiotomies or cesarean deliveries. In addition, GBS has been increasingly reported as being responsible for invasive disease in elderly and immunocompromised patients. In non-pregnant adults, GBS diseases include arthritis, endocarditis, pneumonia, bacteremia and urinary tract infections, as well as soft tissue, skin, and bone infections. Susceptibility to GBS is increased in the elderly and immunocompromised individuals with underlying conditions such as diabetes, cancer, and HIV ([@B131]; [@B37]; [@B116]; [@B134]; [@B140]). Overall neonatal as well as adult infections are, to a large percentage, endogenous infections with colonization of gastrointestinal and vaginal mucosal surfaces as a first crucial step. Nevertheless, in many cases, GBS persists as a commensal bacterium of the microbiota and does not proceed to cause invasive infections. During the last decades, hypervirulent clones have been identified and GBS regulators have been characterized that control the expression of major virulence factors, however, the switch from commensal to invasive pathogen is still incompletely deciphered. Understanding the determinants of GBS mucosal colonization as well as the different stages of the pathobiont lifestyle at a molecular level is therefore important for the development of prevention strategies to control invasive GBS disease. This review combines for first time epidemiological data with data on adherence and colonization for GBS. It covers the following aspects: GBS colonization rates and serotype distribution in different countries and the molecular epidemiology of GBS colonization, determined through MLST sequence types. Adherence properties of GBS will be summarized under the following headings, biofilm formation, and GBS colonization and adherence at a molecular level, which is be subdivided into (i) GBS adhesins to extracellular matrix proteins (ECM), (ii) GBS adhesins to cellular targets, and (iii) GBS pili. The last two sections describe the transition of GBS from commensal to pathogen and current efforts on immunoprophylaxis.

GBS Colonization in Different Countries: Colonization Rates and Serotype Distribution
=====================================================================================

Since vaginal GBS colonization represents the most important risk factor for the development of invasive neonatal infections, colonization rates have been investigated in many different countries. Interestingly the GBS colonization rate among pregnant women in vagina and/or rectum is quite similar worldwide with some variations ranging from 10 to 30% in United States, 6.5% up to 36% in Europe, 7.1 to 16% in Asia, 9.1 to 25.3% in the Middle East, and 11.9 to 31.6% in Africa ([@B131]; [@B9]; [@B55]; [@B156]). The GBS colonization status, however, is intermittent and can be transient during pregnancy. Positive colonizers in early or mid-pregnancy may turn into negative colonizers at delivery ([@B46]; [@B156]). Hence, timing of GBS screening and specimen collection is important to accurately predict colonization status at delivery. According to the CDC guidelines, the intrapartum colonization status is best determined in the late third trimester at no more than 5 weeks before delivery ([@B156]).

While GBS colonization rates may appear quite similar in different regions of the world, serotype prevalence and distribution is geographically distinct. Serotype classification is based on a sialic acid-rich capsular polysaccharide (CPS) which is one of the most important virulence factors in GBS that is involved in GBS persistence and survival within the host. CPS plays a critical role in immune evasion through its mimicry with the host carbohydrate epitopes. It also interferes with the complement-dependent defense pathways, dampens the phagocytic function of neutrophils and facilitates bacterial internalization and intracellular survival inside dendritic cells. Moreover, CPS has been reported to mediate biofilm formation of GBS in the presence of human plasma ([@B79]; [@B114]; [@B17],[@B18]; [@B158]). At present, as many as 10 serotypes (Ia, Ib, and II--IX) are recognized ([@B141]; [@B77]). The distribution and predominance of certain serotypes is susceptible to variations and can change over time. Serotypes Ia, Ib, II, III, and V are prevalent colonizers in the United States and Europe ([@B60]; [@B55]; [@B69]; [@B103]; [@B40]; [@B35]). Serotypes VI and VIII are the most prevalent among pregnant women in Japan ([@B68]; [@B101]) while serotypes IV and V predominate in the United Arab Emirates and Egypt, respectively ([@B5]; [@B137]). Serotype Ia is common in Mexico and is consistently higher in North America in comparison to other areas ([@B55]). The most recently characterized novel GBS serotype IX was reported from Denmark ([@B141]). The geographical distribution of the most prevalent colonizing serotypes is shown in **Table [1](#T1){ref-type="table"}**. On the other hand, serotype III is the most dominant invasive clone accounting for the majority of late-onset meningitis cases in neonates ([@B70]; [@B149]; [@B10]; [@B40]; [@B3]) while serotype Ia and V are dominant invasive isolates in non-pregnant cases ([@B116]; [@B3]). However, recent studies indicate the emergence of invasive serotype IV strains in neonates and adults ([@B38]; [@B150]; [@B3]) and among colonizing strains ([@B29]). A similar scenario could be expected for serotypes VI and VIII which are rarely reported outside Japan. In Malaysia, serotype VI was found among the dominant colonizing strains and the second most common isolate in adults with skin and soft tissue infections due to GBS ([@B62]; [@B27]). In Egypt, serotype VI was reported as a common colonizing serotype in women ([@B137]). And recently, [@B85] reported a clonal dissemination of serotype VI among colonizing and invasive isolate in central Taiwan. Likewise, several studies identified sporadic strains of serotype VIII both as colonizing strains and as causative agents for invasive GBS disease ([@B110]; [@B54]; [@B34]; [@B62]; [@B55]; [@B3]). Similar serotype emergence was earlier reported for serotype V in the United States and in Europe ([@B51]; [@B39]). An increasing diversity of GBS serotypes, as well as serotype switching, represent powerful immune evasion strategies that may severely impair vaccine efforts, that currently rely on a conjugate vaccine incorporating a limited number of GBS serotypes. A close monitoring of the changing serotype distribution occurring in many different countries is therefore crucial in guiding GBS vaccination development.

###### 

Geographical distribution of the most prevalent colonizing group B streptococcus (GBS) serotypes.

  Most prevalent colonizing serotype(s)   Region                                 Reference
  --------------------------------------- -------------------------------------- -------------------------------------------------
  Ia, Ib, II, III, V                      North America, United States, Europe   [@B60]; [@B55]; [@B69]; [@B103]; [@B40]; [@B35]
  Ia                                      Mexico                                 [@B55]
  IV, Ia                                  United Arab Emirates                   [@B5]
  V                                       Egypt                                  [@B137]
  Ia, VI                                  Malaysia                               [@B62]; [@B27]
  VI, VIII                                Japan                                  [@B68]; [@B101]

Epidemiology of GBS Colonization: MLST Sequence Types
=====================================================

Capsular serotyping is the traditional tool used in GBS classification for epidemiological purposes. However, in the era of molecular epidemiology with the availability of numerous bacterial genomes and novel nucleotide sequencing-based tools our traditional picture of GBS epidemiology changed. In respect to corresponding genomes, gene content does not necessarily correlate with the assigned serotype. In 2003, a seven-gene multilocus sequence typing scheme (MLST) was introduced for GBS classification. First studies employing this MLST scheme revealed that capsular serotype is not restricted to a particular MLST sequence type (ST) and GBS strains with the same ST may have different serotypes ([@B61]). Several STs are grouped into clonal complexes (CC) when sharing six or seven matching alleles. The number of a particular CCs is designated after its ancestor ST or the predominant ST within this clone ([@B88]). By MLST the vast majority of the human GBS isolates can be grouped into six CCs which are CC1, CC10, CC17, CC19, CC23, and CC26 ([@B142]; [@B25]). Interestingly, most of the bovine strains were exclusively designated as subtypes of the CC61 and CC67 which have never been reported for any of the human strains ([@B11]; [@B147]; [@B142]; [@B159]; [@B144]).

With the availability of MLST data, it became clear that GBS strains of certain CCs possess a higher potential to cause invasive disease, while other harbor mainly colonizing strains. MLST for a global GBS collection identified STs 1 and 19 to be significantly more associated with asymptomatic colonization and ST-23 was common for carriage and invasive GBS ([@B61]). This is in agreement with a study ([@B97]) that reported STs 1, 19, and 23 as the predominant colonizers in pregnant women and identified them as being well adapted to the vaginal mucosa with a poor invasion ability. Consistently, [@B152] found STs 1 and 23 the most frequent clones in colonized pregnant women. In general, the dominance of strains belonging to CCs 1, 23, and 19 among asymptomatic pregnant women was consistently reported ([@B61]; [@B88]; [@B144]), indicating that for these CCs being a mucosal commensal predominates.

A major clone responsible for a large proportion of invasive neonatal infections are the CC17 strains mostly belonging to serotype III. ST-17 strains first gained special interest due to their strong association with neonatal meningitis. Strains belonging to the CC17 are reported to be hypervirulent accounting for more than 80% of the GBS late-onset neonatal infections and are often but not exclusively associated with meningitis ([@B61]; [@B70]; [@B98]; [@B149]; [@B10]; [@B40]). Comparative phylogenetic analysis of human and bovine isolates revealed CC17 strains as a homogenous group with a recent origin and limited recombination in comparison to other CCs ([@B142]; [@B25]). Moreover, evolutionary analysis between GBS isolates of human and bovine origin found ST-17 as the only human lineage that is clustered within the bovine population ([@B11]). The investigation suggested ST-17 to have bovine ancestors ([@B11]), which was supported by another study ([@B49]) providing evidence for a bovine origin of CC17 by investigating the prevalence of mobile genetic elements. However, a very close connection between the bovine CC67 and the human CC17 was also challenged by a more comprehensive genetic analysis of 238 bovine and human strains ([@B142]). The emergence of a highly virulent GBS clone, causing a large majority of neonatal infections, from a bovine ancestor provides intriguing phylogenetic aspects for placing GBS close to zoonotic diseases. Thus the question of how zoonotic GBS may be is currently controversially discussed and represents an exciting and ongoing scientific question to be solved.

For adult invasive infections, molecular clones other than CC17 are important. A significant percentage of GBS invasive disease in non-pregnant adults is resulting from strains belonging to serotype V ([@B116]; [@B69]; [@B153]; [@B39]). Molecular epidemiology revealed a remarkable association of ST-1, a subtype of CC1, with serotype V GBS causing invasive disease. ST-1 invasive isolates from adults and neonates are mostly belonging to serotype V ([@B125]). A recent analysis of a large cohort of GBS isolates of invasive serotype V strains from adults in United States and Canada ([@B39]). reported 92% of the serotype V strains as ST-1 whereas the most predominant sequence type among the non-ST-1 clones was ST-19. The authors regard the emergence of ST-1 strains as a leading cause of adult disease in the 1990s. Similar to human ST-17, the human ST-1 is suspected to originate from a bovine ancestor. Whole-genome sequencing recognized a 1992 ST-1 clone to be closely related to a 1970s Swedish strain causing cow mastitis. The ST-1 human GBS were found to possess mutations at loci involved in capsule production, pilus expression, and two-component regulatory systems ([@B39]) which all have been reported as key virulence factors in GBS ([@B94]; [@B117]) and may thus represent the adaptation of this strain to human infections.

Particular interest should also be paid to the increasing emergence of type IV among colonizing and invasive GBS isolates. In several recent investigations, this serotype appears to be a hotspot for genetic recombination events, supported by the detection of serotype IV strains with different genetic backgrounds. Multiple studies demonstrated ST-196 as the most frequent sequence type of serotype IV isolates ([@B43]; [@B49]; [@B100]; [@B155]; [@B74]; [@B29]). However, other investigations reported the STs 452 and 459, belonging to CCs 23 and 1, respectively, as the predominant colonizing type IV strains and found ST-196 less frequently ([@B29]; [@B38]; [@B152]). Comparing a collection of emerging type IV isolates in United States belonging to two distinct time periods from 1995 to 2000 and from 2004 to 2008, the older strains were more like a 1970s prototype reference strain with similar PFGE profiles whereas the more recent isolates showed PFGE profiles with considerable differences ([@B29]). Independent studies identified the invasive characteristics of type IV strains to be a result of capsular switching in CC17 strains accompanied with the acquisition of the HvgA adhesin, which has initially been isolated from hypervirulent CC17 serotype III strains ([@B153]; [@B3]). Capsular switching events of CC17 strains have previously been observed ([@B25]) leading to serotype IV ST-256 lineage.

For colonizing as well as invasive GBS strains dominant serotype-MLST genotypes associations have been observed such as serotype III with ST-17, serotype V with ST-1 and serotype IV with ST-196. Unusual associations are most likely to be due to capsular switching which resulted from recombination events around the capsular locus ([@B152]). Investigation of the increase of type IV strains suggested the evolution of hybrid genomes including sequences from hypervirulent ST-17 strains ([@B151]). Thus growing evidence points to an ongoing emergence of novel virulent GBS clones requiring continuous epidemiological surveillance.

Biofilm Formation
=================

Colonization and persistence in different host niches is dependent on the adherence capacity of GBS to host cells and tissues. This then facilitates bacterial cell aggregation and formation of sessile communities known as biofilms. Bacterial biofilms represent well-known virulence factors with a vital role in persistence and chronic infections. In the host environment, bacteria are often protected from the immune system by building sessile colonies embedded in an extracellular matrix of polysaccharides representing the biofilm. For GBS the bacterial capsule and type IIa pili have been demonstrated to play an important role in biofilm formation ([@B66]; [@B158]). Host environmental conditions are crucial determinants in developing bacterial biofilms ([@B23]; [@B81]; [@B107]; [@B121]). Contradictory data are available concerning the environmental cues favoring biofilm communities in GBS ([@B121]). As a normal inhabitant of the vagina, acidic pH seems to be optimal for GBS colonization. Early investigations reported enhanced GBS adherence to vaginal epithelial cells under low pH in comparison to neutral pH ([@B160]; [@B148]). In line with these observations, a significantly higher biofilm production of colonizing GBS isolates from pregnant women was demonstrated at pH 4.5 vs. pH 7 ([@B52]). Similarly, enhanced biofilm formation of GBS was shown under acidic pH conditions in comparison to neutral pH with the strongest biofilm producing GBS isolates belonged to the ST-17 sequence type. In respect to GBS origins, higher frequencies of strong biofilm producers were found among neonatal strains in comparison to colonizing strains ([@B32]). However, a recent investigation reported invasive GBS belonging to CC17 and CC19 lineages as weak biofilm formers while GBS isolated from asymptomatic carriers were found to be strong biofilm producers ([@B112]). One possible explanation for this discrepancy is the experimental set up of the study since GBS biofilm formation was tested at neutral pH conditions and not under acidic pH. Furthermore, the presence of human plasma was shown to promote GBS biofilm formation ([@B158]).

In summary, biofilms allow long-term bacterial persistence and protect bacteria from recognition by the immune system. For GBS low pH and the presence of plasma appear as crucial environmental factors through controlling the expression of bacterial surface-associated structures, such as pili and the capsule, which are both involved in promoting bacterial biofilm formation.

GBS Colonization and Adherence at a Molecular Level
===================================================

GBS Adhesins to Extracellular Matrix Proteins
---------------------------------------------

As an opportunistic commensal constituting a part of the intestinal and vaginal physiologic flora, GBS colonization, persistence, translocation, and invasion of host barriers are largely dependent on their adherence abilities to host cells and ECM ([@B139]; [@B73]). Functionally characterized adhesins mediating GBS adherence and/or invasion within the host are the fibrinogen-binding proteins (Fbs), the laminin-binding protein (Lmb), the group B streptococcal C5a peptidase (ScpB), the streptococcal fibronectin-binding protein A (SfbA), and the GBS immunogenic bacterial adhesin (BibA). In addition, surface-protruding structures comprised of multiples genes like pili are considered as essential adhesins in promoting GBS colonization, persistence, biofilm production, and central nervous system invasion. Major adhesins mediating GBS interaction with host cells are depicted in **Figure [1](#F1){ref-type="fig"}**.

![Major adhesins mediating *Streptococcus agalactiae* (GBS) interaction with host cells. GBS colonization, persistence, translocation, and invasion of host barriers are largely dependent on their ability to adhere to host cells and extracellular matrix proteins (ECM), an important step in breaching cellular barriers. The best characterized surface proteins mediating GBS adherence are the fibrinogen-binding proteins Fbs (including FbsA, FbsB, FbsC, or BsaB, the serine-rich repeat glycoproteins Srr1 and Srr2), the laminin-binding protein (Lmb), the Streptococcal C5a peptidase from group B (ScpB), the streptococcal fibronectin-binding protein A (SfbA), and the GBS immunogenic bacterial adhesin BibA. In addition, surface-protruding structures like pili are considered as essential adhesins in promoting GBS colonization, persistence, biofilm production, and central nervous system invasion. Associated virulence traits are illustrated for each adhesin as follows. FbsA was mainly shown to promote adherence whereas FbsB was shown to be required for invading human cells. Srr1 and Srr2 were reported to mediate invasion of microvascular endothelial cells. Additionally, Srr1 was demonstrated to promote vaginal colonization and persistence. FbsC was recently characterized to promote invasion of epithelial and endothelial barriers and biofilm formation. The Lmb adhesin appears to have a pronounced role in bacterial tropism of the central nervous system (CNS). ScpB interrupts complement activation through cleaving the neutrophil chemoattractant C5a. It is also involved in invasion of human epithelial cells. The SfbA adhesin is involved in human brain microvascular endothelial cells invasion. Furthermore, SfbA contributes to GBS invasion of vaginal and cervical epithelial cells and hence may take part in GBS colonization and niche establishment in the vagina. BibA was reported to aid GBS survival in human blood through interfering with the classic complement pathway by binding the C4-binding protein and by conferring anti-phagocytic activity against opsonophagocytic killing by human neutrophils. HvgA is specific for the hypervirulent clone ST-17. It was suggested to promote meningeal tropism in neonates. Pili in GBS have been shown to be primarily involved in epithelial cell colonization, biofilm formation, translocation, and invasion. PI-1 pili were also found to play an important role in evasion of innate immunity mechanism. The PI-2b protein, however, was demonstrated to increase the intracellular survival in macrophage. Pilus 2b was further identified as important for infection and penetration of the blood brain barrier.](fmicb-09-00437-g001){#F1}

Up to date, five Fbs have been characterized in GBS; FbsA ([@B130]), FbsB ([@B45]), the serine-rich repeat glycoproteins Srr1 and Srr2 ([@B136], [@B135]), and recently FbsC or BsaB ([@B16]; [@B57]). In general, invasive GBS isolates display stronger fibrinogen-binding abilities in comparison to colonizing ones ([@B120]). FbsA was mainly shown to promote adherence ([@B130]) whereas FbsB was shown to be required for invading human cells ([@B45]). Srr1 and Srr2 were reported to mediate invasion of microvascular endothelial cells ([@B136], [@B135]). Additionally, Srr1 was demonstrated to promote vaginal colonization and persistence, since a Srr1-deficient mutant displayed reduced persistence in a mouse GBS vaginal colonization model ([@B138]). FbsC was recently characterized to promote invasion of epithelial and endothelial barriers. FbsC deletion mutant of GBS displayed a drastic reduction in abilities for adherence, invasion and biofilm formation. Besides, virulence abilities of FbsC deletion mutant were impaired in murine infection models ([@B16]). Interestingly, the fibrinogen-binding abilities of the hypervirulent CC17 clones are mainly attributable to FbsB more than FbsA. Deletion mutants of *fbsB* displayed 78--80% reduction in their binding abilities vs. 49--57% as encountered with *fbsA* deletion mutants of CC17 strains ([@B2]). Accordingly, the relative transcription level of *fbsB* was up to 12.7-fold higher than *fbsA* gene in CC17 stains ([@B2]). Moreover, Srr2 was highly expressed and exclusively detected in ST-17, however, Srr1 was absent ([@B133]; [@B135]). Furthermore, CC17 strains are devoid of FbsC. The *fbsC* gene is not adequately expressed in CC17 strains because of a lineage-dependent frameshift mutation ([@B16]).

In addition to the Fbs family, the Lmb adhesin appears to have a pronounced role in bacterial tropism of the central nervous system. [@B143] reported Lmb to be essential for GBS colonization of damaged epithelium and subsequent translocation into the bloodstream. This role was later confirmed by [@B154] as they demonstrated mutation of the *lmb* gene to result in a dramatic reduction in GBS invasion of the brain microvascular endothelial cells. In consistence, [@B1] displayed higher expression levels of Lmb in GBS strains associated with meningitis in comparison to other isolates whereas the expression levels of other ECM-binding proteins, such as ScpB mediating fibronectin binding ability, remained unchanged.

ScpB or the group B ScpB is a surface associated serine protease that both interrupts complement activation through splitting the neutrophil chemoattractant C5a and mediates bacterial binding to fibronectin ([@B22]; [@B12]; [@B21]; [@B86]). The fibronectin binding ability conferred by the *scpB* gene appears to be involved in cellular adherence and invasion. In frame deletion mutation of *scpB* gene significantly reduced invasion of human epithelial cells *in vitro* ([@B21]). Strikingly, *scpB* and *lmb* genes were found to be encoded on a composite transposon where the *scpB* gene is positioned directly upstream of the *lmb* gene. The *scpB-lmb* intergenic region has been described as a hot spot for integration of the GBS mobile genetic elements GBSil and IS*1548* which are located in the promoter region of the *lmb* gene ([@B41]; [@B44]; [@B87], [@B88]; [@B14]). [@B1] reported a marked increase in the transcription levels of *lmb* gene for invasive GBS isolates carrying IS*1548* in the *scpB-lmb* intergenic region associated with an increased laminin binding ability. However, no influence was observed on the *scpB* gene. Deletion mutation of IS*1548* revealed IS*1548* to act as an *lmb* gene up-regulator when compared to the wild-type parent strains. Interestingly the ability of GBS to colonize human mucosal surfaces seems to be closely linked to the presence of this composite transposon carrying *scpB* and *lmb*. In a large percentage of bovine strains, the encoded genes are absent while the presence in human colonizing strains, as well as invasive strains, is close to 100% ([@B41]; [@B142]; [@B118]).

More recently, a novel GBS fibronectin binding protein has been identified ([@B106]). It was designated as streptococcal fibronectin-binding protein A (SfbA) and reported to be highly conserved in GBS mediating cellular invasion but not adherence. SfbA was shown to be directly involved in fibronectin binding and human brain microvascular endothelial cells invasion. When expressed in recombinant non-pathogenic *Lactococcus lactis*, fibronectin binding ability was significantly greater in comparison to a SfbA negative control strain. The investigation also demonstrated SfbA to be primarily involved in brain microvascular endothelial cells invasion. Infection of mice with *sfbA* mutants resulted in a reduced ability to breach the blood brain barrier and subsequent meningitis. This is supported by a study showing SfbA to be crucial for invasion of astrocytes which are physically associated with the brain endothelial cells ([@B146]). Furthermore, SfbA contributes to GBS invasion of vaginal and cervical epithelial cells and hence may take part in GBS colonization and niche establishment in the vagina ([@B106]). Another fibronectin binding protein was described in 2014 ([@B57]). BsaB or the bacterial surface adhesin of GBS is a fibronectin and laminin-binding protein which is involved in GBS binding to epithelial cells and in biofilm formation. Deletion of *bsaB* gene and a cotranscribed upstream region significantly abrogated GBS adherence to VK2 vaginal epithelial cells *in vitro* and immobilized fibronectin. However, genome and sequence analysis revealed BsaB and FbsC as identical proteins encoded by the same gene ([@B16]). The obtained results are in agreement with [@B57], except that FbsC or BsaB was found to mediate GBS attachment to fibrinogen instead of fibronectin. Hence, BsaB was renamed to FbsC.

The multitude of GBS adhesins allowing attachment to different ECM, stresses the importance of this step in GBS pathogenesis, which was confirmed in different *in vivo* models. In this regard, fibrinogen binding may play an especially important role as demonstrated by the presence of numerous fibrinogen binding proteins. These may represent a kind of "backup" system in cases where the primary fibrinogen adhesin was rendered non-functional.

GBS Adhesins to Cellular Targets
--------------------------------

Besides adherence to ECM, the adhesion to host cells plays an important role in the pathogenesis of GBS. An essential adhesin in this context is the GBS immunogenic bacterial adhesin (BibA). It is a cell wall-anchored protein which is well-conserved in GBS and is involved in bacterial binding to human epithelial cells ([@B128], [@B127]). A knockout mutant displayed impaired adherence capacity to the lung, intestinal, and cervical epithelial cells ([@B128]). Overexpression of BibA resulted in increased adherence to human epithelial cells in recombinant wild-type strains harboring a *bibA* plasmid ([@B128]). In addition, BibA was reported to aid GBS survival in human blood through interfering with the classic complement pathway by binding the C4-binding protein and by conferring anti-phagocytic activity against opsonophagocytic killing by human neutrophils ([@B128], [@B127]). A total of four variants of BibA (I, II, III, and IV) were described in GBS ([@B13]; [@B128], [@B127]). Interestingly, variant IV, which was found to be highly similar to the bovine BibA counterparts, was exclusively associated with ST-17 strains ([@B70]; [@B127]). Thus, BibA seems to be a multifactorial virulence factor in regard to GBS as a pathobiont. It contributes to GBS mucosal colonization and adherence to host cells and then confers resistance to phagocytic killing at a stage when the switch to invasive GBS infection has occurred.

The GBS hypervirulent adhesin (HvgA) is a novel cell wall anchored protein that is specific for the hypervirulent clone ST-17. It was first described ([@B149]) as being strongly associated with ST-17 causing neonatal meningitis in LOD. It was suggested to promote meningeal tropism in neonates through efficient intestinal colonization and subsequent translocation across the intestinal and the blood brain barriers. Bypassing intestinal colonization by intravenous infection resulted in a significant decrease in the amount of bacteria reaching the central nervous system. HvgA was required for intestinal colonization in orally infected mice for meningitis development. In addition, HvgA was found to mediate GBS adherence to intestinal epithelial cells, choroid epithelial cells, and microvascular endothelial cells ([@B149]). Clones expressing HvgA exhibited greater adherence abilities than non-expressing ones. HvgA thus contributes to colonization as well as invasion of hypervirulent clones ([@B149]).

GBS Pili
--------

Further structures that are crucial for GBS adhesion are pili. Different from their Gram-negative counterparts, pili in GBS have been shown to be primarily involved in epithelial cell colonization, biofilm formation, translocation, and invasion. Pili are cell-wall anchored appendages extending from the bacterial surface. They contain covalently linked multimeric motifs that are composed of three pilin proteins, the pilus shaft backbone protein (BP) or PilB subunits, and the two ancillary proteins AP1, AP2 located at the pilus tip (PilA subunit, the pilus-associated adhesin) and pilus base (PilC subunit, the pilus anchor), respectively, ([@B31]; [@B122]; [@B95], [@B96]; [@B24]). While PilB has been shown to be involved in bacterial invasion and paracellular translocation mediating resistance to phagocytic killing and virulence, PilA was found contributing to cellular adherence and colonization ([@B31]; [@B67]; [@B95], [@B96]; [@B115]; [@B138]). Three pilus variants named PI-1, PI-2a, PI-2b were reported in GBS representing two pilus islands (PI) where PI-2a and PI-2b are variants of the pilus island 2 (PI-2). All characterized GBS strains harbored at least one variant or a combination of two pilus islands ([@B122]; [@B99]; [@B144]). PI-1 pili were also found to play an important role in evasion of innate immunity mechanism. They diminished macrophage-mediated phagocytic killing of GBS by 50% with no influence on complement-promoted opsonophagocytic killing by neutrophils ([@B56]). Strikingly, PI-1 pili do not appear to contribute to bacterial adhesion to lung, vaginal or cervical epithelial cells ([@B56]). The PI-2a pili were found to have a specific involvement in adherence and biofilm formation and not PI or PI-2b ([@B66]; [@B119]). The PI-2b protein, however, was demonstrated to increase the intracellular survival in macrophage ([@B19]). In addition, a special role for pilus type 2b has been suggested in promoting strain invasiveness and bacterial host cell interactions. Mutants of pilus 2b possess less adherence and invasion capacities for epithelial and endothelial cells ([@B76]). Pilus 2b was further identified as important for infection and penetration of the blood brain barrier. These results are supported by an investigation of the distribution of pilus islands among GBS strains belonging to ST lineages of human and bovine origin ([@B144]). In addition, the distribution of pili islands appears to determine the capacity for colonization or invasive infections. Invasive GBS were more likely to carry a combination of PI and one of the PI-2 variants in comparison to maternal colonizing isolates. Moreover, GBS causing invasive neonatal disease including all CC-17 strains were harboring PI-1 plus PI-2b. Earlier genomic studies showed pilus type 2b to be conserved in the ST-17 hypervirulent clone ([@B13]). Interestingly PI-2b pilus variants are almost exclusively present in bovine GBS isolates. These bovine strains mostly lack PI-1, unlike the human isolates which commonly encode the pilus PI-1 in association with one of the PI-2 variants ([@B144]).

GBS Transition From Commensal to Pathogen
=========================================

Group B streptococcus is a commensal bacterium of the vagina and the gastrointestinal tract of healthy adults. However, as a pathobiont, GBS can convert from the asymptomatic mucosal carriage state to a bacterial pathogen causing invasive infections. For neonatal infections that implies a switch from bacterial survival in the acidic host environment of the vagina to resistance of the immune system in the pH neutral environment of human blood. To address bacterial adaptation to these environmental changes, a genome-wide transcription analysis was performed in order to investigate GBS responses to acid stress in comparison to neutral pH conditions ([@B126]). This study demonstrated the modulation of genes involved in GBS adaptation and vaginal persistence as well as virulence-related genes in response to fluctuating environmental pH which are mostly under the control of the CovRS two-component regulatory system (TCS). Among the adherence factors that were demonstrated to be under the control of CovRS are Fbs proteins, Lmb, C5a, BibA, HvgA, and pili ([@B71]; [@B59], [@B56]; [@B126]; [@B149]; [@B111]). These observations suggested that GBS translocation from acidic to neutral niches switches on virulence-related genes, favoring the transition from commensal to invasive bacterial pathogen. The CovRS system is a well-studied TCS in GBS and a major virulence regulator. The contribution of CovRS in coordinating GBS gene expression and virulence has been investigated in many studies ([@B71]; [@B58], [@B59]; [@B28]; [@B36]). [@B113] conducted a global transcription profiling of human vaginal epithelial cells exposed to a CovR-deficient mutant in comparison to the wild-type strain and studied a mouse model of GBS vaginal colonization. Their major observation was that loss of CovR signaling promoted exaggerated host inflammatory reactions against GBS infection. Hence, the authors concluded that CovRS control of GBS virulence gene expression is crucial in maintaining GBS vaginal colonization by avoiding host immune responses ([@B113]). Apart from regulation through TCS, GBS genomic adaptations seem to take place during GBS transition from commensal to pathogen. Comparing the whole genomes of GBS pairs from infected newborns and their mothers genomic mutations were found with critical phenotypic impacts, including CovR mutations ([@B4]). Genomic adaptations may also impact dynamics of maternal GBS colonization before and after delivery. Alterations in STs and serotypes can be observed in 18.3% of pregnant women who were positive colonizers before and after delivery ([@B97]). Definite STs appear to be related with GBS clearance and persistence. Not surprisingly capsule expression is linked to invasion capabilities of GBS. A significantly higher proportion of non-typeable strains are present among colonizing isolates in comparison to invasive isolates ([@B152]). This may indicate that persistent colonizers undergo several lateral DNA exchanges leading to the abolishment of capsule expression since encapsulation is less important during carriage. Capsule loss has previously been suggested to favor GBS colonization and diminish virulence ([@B123]) and capsule production is also regulated through CovRS. Thus the results of multiple independent investigations strengthen the role of CovRS as a central GBS regulator controlling the switch from mucosal colonization to invasive infection.

Immunoprophylaxis
=================

The ability of GBS to cause neonatal invasive infections is dependent on the maternal antibody titer. Early work done by Rebecca Lancefield in the 1930s ([@B72]) reported protection against GBS infection in mice by CPS-specific antiserum in rabbits. [@B8] demonstrated an inverse association between the levels of maternal serotype-specific capsular antibodies and the increased susceptibility to invasive GBS disease in newborns. This association was confirmed in later investigations ([@B83], [@B84]; [@B7]). Vaccination seems, therefore, to be a good alternative to peripartal antibiotic prophylaxis in order to prevent neonatal GBS infections. However, no licensed vaccines are available ([@B156]; [@B90]). The sialylated CPS has been the main target for GBS vaccine in most clinical trials. Phases I and II clinical trials demonstrated the safety and immunogenicity of monovalent CPS-conjugate vaccines among healthy women ([@B109]). However, monovalent formulations with serotype-specific immune responses are not sufficient to provide protection against the different GBS serotypes found in invasive infections. Besides, possible capsular switching forced by the selective pressure exerted due to GBS monovalent vaccines can be expected. Multivalent formulations would provide broader vaccine coverage and overcome problems of serotype switching ([@B60]; [@B15]; [@B108]; [@B47]). The Safety and immunogenicity of a trivalent GBS conjugate vaccine based on serotypes Ia, Ib, and III have has been evaluated in Phases I and II trials and there are considerations for a Phase III trial ([@B91]; [@B30]; [@B50]; [@B64],[@B65]; [@B80]; [@B89]). Pre-clinical studies of a pentavalent vaccine, based on serotypes Ia, Ib, II, III, V are currently under investigation ([@B64]). In addition to serotype-specificity, the development of a GBS vaccine with global relevance is a real challenge due to geographic serotype diversity and variations over time. Hence, new vaccine candidates based on conserved surface proteins have been investigated and these included ScpB, Lmb, surface immunogenic protein Sip, leucine rich repeat protein LrrG, Rib and tandem-repeat containing α and β components of the C protein ([@B157]; [@B124]; [@B105]; [@B92]; [@B145]; [@B143]; [@B20]; [@B48]; [@B132]). A Phase I clinical trial revealed the immunogenicity of Rib and α-C surface proteins against invasive GBS disease ([@B90]). Based on reverse vaccinology utilizing genomics, proteomics, transcriptomics and *in silico* technologies, a panel of potential vaccine targets could be discovered ([@B60]). A similar approach also lead to the identification of GBS pili ([@B75]). However, the development of a pilus-based vaccine has been hampered due to antigenic variations of pili in GBS ([@B99]; [@B108]), but structural vaccinology may overcome this problem. Crystallographic structure of the BP-2a pilus subunit showed four IgG-like domains D1, D2, D3, and D4. Since the D3 domain elicited similar protection as the whole BP-2a component, a promising hybrid vaccine candidate consisting of 6xD3 of the D3 domains from six variant BP-2a pilus subunits was constructed. It is expected to confer protection against all six pilus variants found in GBS strains ([@B108]). Other promising vaccine targets that have been identified by reverse vaccinology include the Sip and BibA proteins ([@B93]; [@B128], [@B127]). It has been recently shown that a reduced likelihood of maternal GBS acquisition during pregnancy is directly associated with Sip and BibA induced antibodies ([@B33]). The successful development and introduction of a GBS vaccine may, therefore, result in converting GBS into a predominantly harmless commensal of the mucosa.

Conclusion
==========

Group B streptococcus adherence and colonization is a complex multifactorial process which determines the success of a pathobiont in the human ecosystems. GBS possess strict regulatory systems which are responsible for fine-tuning the expression of adhesins in order to optimize GBS fitness under the prevailing environmental conditions. Long-term colonization and persistence is largely dependent on the ability of GBS to avoid the host immune response. Over the last two decades, a detailed knowledge about molecular adhesion mechanisms was accumulated for GBS, which considerably enhances our understanding of disease development. These GBS adhesion determinants may represent novel targets for the development of innovative treatment and prophylaxis strategies aiming at control and prevention of invasive GBS disease in neonates as well as adult patients. To date, the sialic acid-containing CPS that underlies the serotyping system of GBS has been the main focus of most vaccine developments. GBS colonizers represent the silent reservoirs responsible for serotype diversity and evolutionary changes in virulence determinants. Investigation of GBS population structure is essential to monitor the circulating serotypes and identify changes in strains causing GBS disease. An aspect, which is especially important in view of a possible serotype-dependent vaccination in the near future.
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